MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1053/j.gastro.2019.04.018

Медицинская библиотека · Gastroenterology · 2019

Lanreotide Reduces Liver Growth In Patients With Autosomal Dominant Polycystic Liver and Kidney Disease.

van Aerts Rene M M, Kievit Wietske, D'Agnolo Hedwig M A, Blijdorp Charles J, Casteleijn Niek F, Dekker Shosha E I, de Fijter Johan W, van Gastel Maatje, Gevers Tom J, van de Laarschot Liyanne F M, Lantinga Marten A, Losekoot Monique, Meijer Esther, Messchendorp A Lianne, Neijenhuis Myrte K, Pena Michelle J, Peters Dorien J M, Salih Mahdi, Soonawala Darius, Spithoven Edwin M, Visser Folkert W, Wetzels Jack F, Zietse Robert, Gansevoort Ron T, Drenth Joost P H, DIPAK-1 Investigators

СтатьяРандомизированное исследованиеПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

BACKGROUND & AIMS: Polycystic liver disease is the most common extrarenal manifestation of autosomal dominant polycystic kidney disease (ADPKD). There is need for robust long-term evidence for the volume-reducing effect of somatostatin analogues. We made use of data from an open-label, randomized trial to determine the effects of lanreotide on height-adjusted liver volume (hTLV) and combined height-adjusted liver and kidney volume (hTLKV) in patients with ADPKD.

METHODS

We performed a 120-week study comparing the reno-protective effects of lanreotide vs standard care in 305 patients with ADPKD (the DIPAK-1 study). For this analysis, we studied the 175 patients with polycystic liver disease with hepatic cysts identified by magnetic resonance imaging and liver volume ≥2000 mL. Of these, 93 patients were assigned to a group that received lanreotide (120 mg subcutaneously every 4 weeks) and 82 to a group that received standard care (blood pressure control, a sodium-restricted diet, and antihypertensive agents). The primary endpoint was percent change in hTLV between baseline and end of treatment (week 120). A secondary endpoint was change in hTLKV.

RESULTS

At 120 weeks, hTLV decreased by 1.99% in the lanreotide group (95% confidence interval [CI], -4.21 to 0.24) and increased by 3.92% in the control group (95% CI, 1.56-6.28). Compared with the control group, lanreotide reduced the growth of hTLV by 5.91% (95% CI, -9.18 to -2.63; P < .001). Growth of hTLV was still reduced by 3.87% at 4 months after the last injection of lanreotide compared with baseline (95% CI, -7.55 to -0.18; P = .04). Lanreotide reduced growth of hTLKV by 7.18% compared with the control group (95% CI, -10.25 to -4.12; P < .001).

CONCLUSIONS

In this subanalysis of a randomized trial of patients with polycystic liver disease due to ADPKD, lanreotide for 120 weeks reduced the growth of liver and combined liver and kidney volume. This effect was still present 4 months after the last injection of lanreotide. ClinicalTrials.gov, Number: NCT01616927.

Для цитирования: van Aerts Rene M M, Kievit Wietske, D'Agnolo Hedwig M A, Blijdorp Charles J, Casteleijn Niek F, Dekker Shosha E I, de Fijter Johan W, van Gastel Maatje, Gevers Tom J, van de Laarschot Liyanne F M, Lantinga Marten A, Losekoot Monique, Meijer Esther, Messchendorp A Lianne, Neijenhuis Myrte K, Pena Michelle J, Peters Dorien J M, Salih Mahdi, Soonawala Darius, Spithoven Edwin M, Visser Folkert W, Wetzels Jack F, Zietse Robert, Gansevoort Ron T, Drenth Joost P H, DIPAK-1 Investigators. Lanreotide Reduces Liver Growth In Patients With Autosomal Dominant Polycystic Liver and Kidney Disease.. Gastroenterology. 2019. DOI: 10.1053/j.gastro.2019.04.018.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.